Vivos Therapeutics Q3 EPS $(1.75) Up From $(6.50) YoY, Sales $3.30M Down From $4.25M YoY
Portfolio Pulse from totan@benzinga.com
Vivos Therapeutics, Inc. (VVOS) reported a narrower loss of $(1.75) per share in Q3 compared to $(6.50) per share in the same quarter last year, indicating an improvement in earnings. However, the company experienced a decline in sales, reporting $3.30 million this quarter, a 22.26% decrease from $4.25 million in the same period last year.
November 14, 2023 | 9:22 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Vivos Therapeutics reported a significant reduction in losses per share in Q3, but also a notable decrease in sales compared to the same period last year.
The improvement in earnings per share (EPS) could be viewed positively by investors as it suggests cost management and operational efficiency. However, the decrease in sales might raise concerns about the company's growth and demand for its products. The mixed results present both positive and negative aspects, which could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100